New pharma
Follow
Find
4.9K views | +1 today
New pharma
Pharma's struggle for a new commercial model
Curated by rob halkes
Your new post is loading...
Scooped by rob halkes
Scoop.it!

Working Life: Jane Griffiths - InPharm

Working Life: Jane Griffiths - InPharm | New pharma | Scoop.it

Working Life: Jane GriffithsInPharmI joined Janssen, the pharmaceutical division of Johnson & Johnson, as a sales representative after completing my PhD at the University of Aberystwyth in 1982.

...Now we follow the product in the real patient environment. Health literacy, adherence and patient responsibility are essential to increasing therapeutic effectiveness. Luckily, in today’s world, the patient is an informed participant, and this is also changing the dynamic of healthcare. Rather than simply providing safe and efficacious products, we need to provide healthcare and health services that go beyond the disease, supporting the quality of life of the whole person....

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

My Cancer Circle – Cancer Support Community for Patients and Caregivers

My Cancer Circle – Cancer Support Community for Patients and Caregivers | New pharma | Scoop.it
Visit the My Cancer Circle support group for stories, message boards and other resources for cancer patients, caregivers and family members.
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Lilly launches oncology trial app for healthcare professionals - NEWS - articles - Pharmaceutical Industry - PMLiVE

Lilly launches oncology trial app for healthcare professionals - NEWS - articles - Pharmaceutical Industry - PMLiVE | New pharma | Scoop.it
Pharmaceutical Industry | NEWS | | Lilly launches oncology trial app for healthcare professionals - Aims to increase patient participation in cancer trials | PMLiVE...
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Pinterest: Is This The Next Big Social Media Channel for Pharma?

Pinterest: Is This The Next Big Social Media Channel for Pharma? | New pharma | Scoop.it
So what does all this mean to pharma? Based on the meager existing pharma usage of Pinterest, it's very hard to say. Like all social media, the tool is designed to facilitate conversations between people, a conversation that ...
more...
No comment yet.
Rescooped by rob halkes from 2- HEALTHCARE SOCIAL MEDIA by PHARMAGEEK
Scoop.it!

4 innovative campaigns pushing pharma social media forward #hcsm #hcsmeu #hcsmeufr

4 innovative campaigns pushing pharma social media forward #hcsm #hcsmeu #hcsmeufr | New pharma | Scoop.it

In the grand experiment that is healthcare social media, there have certainly been some hits and misses. The lack of clarity around the ROI in social media for pharmaceutical companies (or anywhere, really) in combination with a lack of comprehensive guidance from the U.S. Food and Drug Administration makes it ground on which drug companies have for the most part have tip-toed. But among removed Facebook pages and shuttered YouTube accounts, a few companies have taken risks and shown us what value social media can have for pharmas.

 

Below are four examples of campaigns that have helped pushed pharmaceutical social media forward:

 

1. Boehringer Ingelheim – Drive4COPD

2. Sanofi Diabetes US

3. Novo Nordisk – Race with Insulin

4. AstraZeneca – Prescription assistance program


Via Parag Vora, Lionel Reichardt / le Pharmageek
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Pharma feeds multiply on Twitter - FiercePharma

Pharma feeds multiply on Twitter - FiercePharma | New pharma | Scoop.it

Pharma feeds multiply on TwitterFiercePharmaAbout half of the companies have just one news stream on the social-media network. Twenty-three have more than one, and one company operates as many as 21, Eye on FDA's census found.

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

The end of drug discovery?

The end of drug discovery? | New pharma | Scoop.it
As budgets are cut and many of the pharmaceutical industry's most lucrative drugs come off patent, will the drug industry be able to make the medicines for the future?
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Pharma marketing research and Web 2.0 | eyeforpharma

Pharma marketing research and Web 2.0 | eyeforpharma | New pharma | Scoop.it
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Should Pharma Go Culture Casting?

Should Pharma Go Culture Casting? | New pharma | Scoop.it
The current pharma landscape still doesn't offer guidelines for social media participation, but it's not stopping patients from talking and influencing their networks. Going culture casting and enlisting the help of the most ...
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Steven Burrill: Can Pharma Turn the Oceanliner Around? | PharmaQbD

Steven Burrill: Can Pharma Turn the Oceanliner Around? | PharmaQbD | New pharma | Scoop.it
To survive, the biotech guru says, Big Pharma must ignore the “gravel in the road” and continue driving towards personalized medicine.
more...
No comment yet.
Rescooped by rob halkes from Pharma
Scoop.it!

Thinking of having a website as the hub of your next campaign to educate doctors? Don't bother

Thinking of having a website as the hub of your next campaign to educate doctors? Don't bother | New pharma | Scoop.it

Just 10 percent of doctors prefer to receive information via pharma websites.

 

A slide excerpted from a Doctors.net.uk presentation by Jo Bell and Tim Ringrose, available here (PDF):

 

http://www.pharmatimes.com/Libraries/web_SOPHIE_docs/Tim_Ringrose_doctors_net_CIRCULATION_slides_1.sflb.ashx


Via Andrew Spong
more...
Sven Awege's comment, May 5, 2012 3:36 AM
How neutral is the audience if they are answering the question on a community platform. Manhattan gives a more representative view.
Clearly Pharma sites do not have same objectives. HCP would not expect to need the Pharma site on a weekly, or even monthly basis, but 3 or 4 times a year might be what good looks like! I'm not a big fan of Pharma sites, but I do wish we'd stop comparing apples with pears!
What does come out of this is that Pharma needs to produce higher quality content or solutions, and work on building more trust through true engagement.
Scooped by rob halkes
Scoop.it!

Study reveals scale of errors on doctors' prescriptions - The Guardian

Study reveals scale of errors on doctors' prescriptions - The Guardian | New pharma | Scoop.it
The GuardianStudy reveals scale of errors on doctors' prescriptionsThe GuardianA study commissioned by the GMC, which regulates doctors, found that over the course of a year, one in 20 prescription items had some sort of error or monitoring of the...
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Pharma Report 2012 Get Back in Shape

Pharma Report 2012 Get Back in Shape | New pharma | Scoop.it
When big pharma looks in the mirror, what does it see A body beset by old, expiring brands and not enough energetic, youthful ones to replace them.
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Pharma rocks many Twitter handles for many reasons - FierceBiotech IT

Pharma rocks many Twitter handles for many reasons - FierceBiotech IT | New pharma | Scoop.it
Pharma rocks many Twitter handles for many reasons

The Twittersphere is lousy with pharma feeds. Count them up, as Eye on FDA recently did, and 44 drugmakers operate 200 Twitteraccounts, and the number appears to be growing as pharma companies raise their online profiles and tailor their social media strategies.

Yet there are gray areas around how to operate in the realm of the social web, calling for careful stewardship of Twitter accounts and Facebookpages, where the possibility exists for companies to have their products and profiles dragged through the digital mud...

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Special report: Pharma and social media | eyeforpharma

Special report: Pharma and social media | eyeforpharma | New pharma | Scoop.it

In this special report, eyeforpharma examines the ways pharma can use social media to engage patients, customers, and payers

more...
No comment yet.
Rescooped by rob halkes from Pharma
Scoop.it!

Pharma digital marketing spend up

Pharma digital marketing spend up | New pharma | Scoop.it

A recent Cutting Edge Information study examining the marketing resource allocations of 15 pharma brands to show how pharma marketing strategies are evolving to stay inline with physician and patient demand for digital information suggests digital marketing spend continues to rise within pharma brand teams.

 

Communiqué reports:

 

'The study considered three critical phases of drug commercialisation: phase III to regulatory approval, approval to launch, and launch to six-months post-launch. On average the 15 pharmaceutical brands spent $150,000 on digital marketing per molecule during the phase IIIA development. This figure then tripled between regulatory approval and immediately after the launch.'


Via Andrew Spong
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

10 Social Media Listening Tools You Probably Haven’t Heard About | Business 2 Community

10 Social Media Listening Tools You Probably Haven’t Heard About | Business 2 Community | New pharma | Scoop.it
It’s time for another round-up of interesting players in the social business space.
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

What are They Tweeting? Uses of Twitter by Pharma… | Eye on FDA

What are They Tweeting? Uses of Twitter by Pharma… | Eye on FDA | New pharma | Scoop.it

Companies appear to be trying to do what social media does – target select audiences with specific messaging – or as I like to call it “niche-casting”. What are the areas of breakdown? Geography – No surprises here, much of ...

more...
No comment yet.
Scooped by rob halkes
Scoop.it!

Enormous value in 'appropriate use' of healthcare data - NEWS - articles - Pharmaceutical Industry - PMLiVE

Enormous value in 'appropriate use' of healthcare data - NEWS - articles - Pharmaceutical Industry - PMLiVE | New pharma | Scoop.it
Pharmaceutical Industry | NEWS | | Enormous value in 'appropriate use' of healthcare data - Report says governments, organisations and individuals could benefit from effective 'trade rules' for data | PMLiVE...
more...
No comment yet.
Rescooped by rob halkes from The Pharmaceutical Industry
Scoop.it!

World’s first stem cell drug approved in Canada | InPharm

World’s first stem cell drug approved in Canada | InPharm | New pharma | Scoop.it
Canada has approved the world’s first stem cell drug, marking an historic day for the burgeoning therapy.

 

Osiris' Prochymal is now approved in Canada in children with graft versus host disease (GvHD), a potentially deadly complication from a bone marrow transplant, when newly implanted cells attack the patient’s body.

 

Prochymal is made up of bone marrow stem cells derived from an adult donor and is designed to control inflammation, promote tissue regeneration and prevent scar formation – GvHD affects around 3,500 to 4,000 worldwide.

 

“Today, Osiris turns the promise of stem cell research into reality, delivering on decades of medical and scientific research,” said Peter Friedli, chairman and co-founder of Osiris.

 

“It took 20 years of hard work and perseverance and I want to personally thank everyone involved for their dedication to this important mission.”

The approval is based on recent trial results that showed statistically significant improvement in survival in patients taking Prochymal, when compared with a historical control population of children with refractory GvHD.

 

Andrew Daly, principal investigator in the Phase III programme for Prochymal, said: “I am very proud of the leadership role Canada has taken in advancing stem cell therapy and particularly gratified that this historic decision benefits children who would otherwise have little hope.

 

“As a result of Health Canada’s comprehensive review, physicians now have an off-the-shelf stem cell therapy in their arsenal to fight GvHD.

“Much like the introduction of antibiotics in the late 1920s, with stem cells we have now officially taken the first step into this new paradigm of medicine.”

It has not been an easy road for the firm - in 2009, two late-stage clinical trials failed to show the drug was more effective overall than a placebo in treating the disease.

 

But it did show promise in certain subgroups of patients, and the firm later re-analysed its data to confirm that its drug could increase survival in this patient population.

 

The Canadian regulators have told Osiris that it must carry out further testing on the drug after it reaches the market.

 

Osiris, which is based in Columbia, Maryland, plans to submit its drug with the FDA by the end of this year, including its newly analysed information.

 

Boost for stem cell research

 

Dozens of adult stem cell therapies are currently moving through clinical trials, and Canada’s approval of Prochymal will be a boost to many working in the field.

 

But the use of stem cells remains controversial, as some are derived from the cells of embryos.

However, stem cells derived from adult tissue such as fat or bone marrow – such as with Osiris’ drug - can get around these ethical concerns.

 

Osiris signed a pact potentially worth around $1.4 billion with Genzyme in 2008 to develop Prochymal and another stem cell drug, Chondrogen, for osteoarthritis.

 

But in February Genzyme, now a part of Sanofi, said it had discontinued its project with Prochymal for GvHD.


Via Thibaud Guymard
more...
No comment yet.
Rescooped by rob halkes from The Pharmaceutical Industry
Scoop.it!

Sales forces shrank in 2011, but not everywhere

Sales forces shrank in 2011, but not everywhere | New pharma | Scoop.it
Pharmas shrank their US sales forces by 7% between 2010 and 2011, but the pain wasn't shared evenly between the biggest of pharmas, as a number of players scaled up.

 

Roche cut deepest among big pharmas, lopping off a third of its Full-Time Rep Equivalents, while Abbott and Sanofi were close behind, downsizing 23% of their FTEs, according to an analysis by Cegedim Strategic Data. GSK cut its FTE force by 22% and Bayer by 19%.

 

But Boehringer Ingelheim and Novo Nordisk went on hiring sprees, bumping up their FTE numbers by 15% and 13%, respectively, while AstraZeneca and Warner Chilcott increased FTEs 11%. Amgen's FTE count was up a whopping 32%. A number of smaller and mid-sized pharmas were hiring, too, including Gilead, Endo, Elorac and Somaxon.

 

Driving hiring at AstraZeneca was promotion of Crestor, the nation's most-detailed brand in 2011 with around 2.5 million details. The next-most-detailed brands were Cymbalta and Bystolic, with 2.1 million details, followed by Celebrex and Seretide, with 1.9 million, Lipitor with 1.7 million, Spiriva with 1.6 million and Symbicort and Pradaxa with 1.5 million.

 

The average length of details declined again in 2011, to under 5 minutes. In 2007, 70% of details were over 5 minutes. Increasingly, said Cegedim, physicians' offices, under pressure from managed care and having increased patient volume to make up for less reimbursement, “are setting aside only a small, highly competitive window of time per week for details,” while others stop seeing reps altogether.

Complicating access for reps is the fact that their employers, seeking cost-savings, are pulling back on samples, which dropped again in 2011, while brochure leave-behinds increased. Reps armed with samples are more likely to get a foot in the door than those carrying only brochures, but samples are costly to companies.


Via Thibaud Guymard
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

ePharma Summit: Sit Down with an #ePharma West Guru: Scott ...

ePharma Summit: Sit Down with an #ePharma West Guru: Scott ... | New pharma | Scoop.it
In a heavily regulated industry like pharma, where other companies are hesitant to engage in social media because of the potential risks, Sanofi US is demonstrating that social media engagement can be highly successful, ...
more...
No comment yet.
Rescooped by rob halkes from Pharma
Scoop.it!

Growing support for co-creation between pharma and patients

Growing support for co-creation between pharma and patients | New pharma | Scoop.it

Support is growing for increased collaboration between pharmaceutical companies and patients in research processes worldwide, according to a new report by GBI Research


Via Andrew Spong
more...
No comment yet.
Rescooped by rob halkes from Pharma
Scoop.it!

Doctors who “Tablet Touch” during details have better iPad rep experiences

Doctors who “Tablet Touch” during details have better iPad rep experiences | New pharma | Scoop.it

A new manhattanResearch report suggests that physicians who touched a sales rep's iPad were more likely to have a satisfactory experience, and more likely to say the experience influenced their clinical decisions.

 

However, only one-quarter of the 30 percent of physicians who saw a sales rep with an iPad actually touched the device during the meeting.

 

[AS: a new chapter in the mythologising of the arcane, totemic qualities of the iPad as an influencer of physician behaviour is written with the release of this data.

 

What exactly is it about the way that content is presented by iOS which leads doctors to feel as though they have been more influenced than they would have done were it presented on either another tablet, or perhaps a laptop?

 

Is it the tactile nature of the experience? The ability of iOS to render graphics? Or a conditioned response on the part of the audience that associates the tablet with other experiences?

 

It is also interesting to note that reps seem unwilling to let the tablet out of their hands, and let the doctor 'drive' the detail. I would have thought '1. pass the iPad to the clinician' was the first item on the Successful Digital Detailing 101 training program.]


Via Andrew Spong
more...
No comment yet.
Scooped by rob halkes
Scoop.it!

TweetPharm Pharma Social Media Infographic | Intouch Solutions

TweetPharm Pharma Social Media Infographic | Intouch Solutions | New pharma | Scoop.it

TweetPharm is a free interactive infographic that tracks pharmaceutical companies' use of Twitter.

more...
No comment yet.